Article 25fa pilot End User Agreement

This publication is distributed under the terms of Article 25fa of the Dutch Copyright Act (Auteurswet) with explicit consent by the author. Dutch law entitles the maker of a short scientific work funded either wholly or partially by Dutch public funds to make that work publicly available for no consideration following a reasonable period of time after the work was first published, provided that clear reference is made to the source of the first publication of the work.

This publication is distributed under The Association of Universities in the Netherlands (VSNU) ‘Article 25fa implementation’ pilot project. In this pilot research outputs of researchers employed by Dutch Universities that comply with the legal requirements of Article 25fa of the Dutch Copyright Act are distributed online and free of cost or other barriers in institutional repositories. Research outputs are distributed six months after their first online publication in the original published version and with proper attribution to the source of the original publication.

You are permitted to download and use the publication for personal purposes. All rights remain with the author(s) and/or copyrights owner(s) of this work. Any use of the publication other than authorised under this licence or copyright law is prohibited.

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please contact the Library through email: copyright@ubn.ru.nl, or send a letter to:

University Library
Radboud University
Copyright Information Point
PO Box 9100
6500 HA Nijmegen

You will be contacted as soon as possible.
Association of the transfer coefficient of the lung for carbon monoxide with emphysema progression in male smokers

F.A.A. Mohamed Hoesein*, P. Zanen*, B. van Ginneken#, R.J. van Klaveren+ and J-W.J. Lammers*

ABSTRACT: A decreased transfer coefficient of the lung for carbon monoxide (KCO) is associated with emphysema. We evaluated whether in heavy smokers, baseline KCO was associated with the progression of computed tomography (CT)-detected emphysema, and the progression of airflow limitation.

Heavy smokers, mean ± SD 41.3 ± 18.7 pack-yrs, participating in a lung cancer screening trial underwent diffusion testing and CT scanning of the lungs. CT scanning was repeated after median (25th–75th percentile) 2.8 (2.7–3.0) yrs and emphysema was assessed by lung densitometry using the 15th percentile. The association between KCO at baseline with progression of emphysema and lung function decline was assessed by multiple linear regression, correcting for baseline CT-quantified emphysema severity and forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC), age, height, body mass index, pack-yrs and smoking status (current or former smoker).

522 participants aged 60.1 ± 5.4 yrs were included. Mean ± SD 15th percentile was -938 ± 19, absolute FEV1/FVC was 71.6 ± 9% and KCO was 1.23 ± 0.25, which is 81.8 ± 16.5% of predicted. By interpolation, a one SD (0.25) lower KCO value at baseline predicted a 1.6 HU lower 15th percentile and a 0.78% lower FEV1/FVC after follow-up (p < 0.001).

A lower baseline KCO value is independently associated with a more rapid progression of emphysema and airflow limitation in heavy smokers.

KEYWORDS: Chronic obstructive pulmonary disease, computed tomography, diffusion testing, emphysema, longitudinal, spirometry

Chronic obstructive pulmonary disease (COPD) is the only chronic disease with increasing mortality rates and is supposed to be the third leading cause of death by 2020 [1]. Since prevention of COPD appears to be more promising than treatment, early recognition of COPD-susceptible subjects is therefore pivotal to reducing the increasing burden of this disease.

COPD is characterised by progressive airflow limitation and consists of chronic bronchitis and emphysema. Chronic bronchitis leads to, for example, increased mucus production in the (smaller) airways causing airway obstruction, while emphysema induces airflow obstruction by loss of elastic recoil of lung tissue. Both can coincide and contribute to a greater degree of airflow obstruction. Currently, in the living subject, emphysema can only be assessed by means of computed tomography (CT) scans and lung densitometry measurements to quantify the extent of the disease. However, there are some disadvantages to CT scanning, most importantly the radiation exposure, the costs and the availability of the equipment [2].

The diffusion capacity of carbon monoxide is an easy-to-perform tool to assess the functionality of the alveolar-capillary membrane and is reported as the transfer coefficient of the lung for carbon monoxide (KCO) [3]. The KCO can be considered as the rate constant for alveolar carbon monoxide uptake and is lowered in the presence of emphysema. HOLME and STOCKLEY [4] showed that a large proportion of subjects with a lowered KCO, but with normal forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) values, show radiological evidence of emphysema. A decreased KCO therefore supports a diagnosis of emphysema in patients with or without airflow limitation.
obstruction and may add to spirometry to establish the diagnosis of COPD [5].

However, little is known about the association between KCO and the natural course of CT-quantified emphysema and FEV1/FVC in heavy, but relatively healthy, smokers. We hypothesised that lower baseline KCO values were associated with a more rapid progression of CT-quantified emphysema and decline in FEV1/FVC. Therefore, the aim of the present study was to assess, first, the relationship between the KCO at baseline and the progression of CT-quantified emphysema, and secondly, the progression of airflow obstruction.

METHODS

Participants
The study was conducted among participants of the Dutch–Belgian Lung Cancer Screening Trial (NELSON) who were recruited by the University Medical Center Utrecht, Utrecht, the Netherlands, as only this centre included diffusion capacity measurements. The NELSON is a population-based CT-screening trial for lung cancer, and inclusion criteria have been published previously [6, 7]. In short, participants meeting the inclusion criteria of having smoked a minimum 20 pack-yrs and being fit enough to undergo potential thoracic surgery were invited to participate. Only males were included based on their high risk of developing lung cancer/COPD, as fewer females in the Dutch population have accumulated a long-term exposure to cigarettes compared with males [5]. Baseline details on smoking habits were gathered through questionnaires, which included questions about duration of smoking, number of pack-yrs smoked and smoking status at enrolment (current or former smoker). It was decided at the start that this study should provide a unique opportunity to also assess lung function and to investigate this in relation to CT measures. Therefore, spirometry was assessed in all individuals.

The NELSON trial was approved by the Dutch Ministry of Health on December 23, 2003, and by the institutional review board of the University Medical Center Utrecht, the Netherlands (approval number 03/040). The NELSON trial is registered at www.trialregister.nl with trial number ISRCTN63545820. Informed consent was obtained from all participants.

Pulmonary function testing
Pulmonary function tests (PFT) included FEV1, FVC, alveolar volume and KCO, which were all carried out according to current European Respiratory Society (ERS) guidelines [8, 9]. Reversibility of airflow obstruction was not assessed. PFT was performed on the same day as the CT scan. Airflow obstruction was defined as an FEV1/FVC below the lower limit of normal (LLN) at baseline [10].

KCO measurements were performed with a MasterLab Pro (Erich Jaeger GmbH, Wurzburg, Germany), with the single-breath manoeuvre method; the test gas contained CO 0.25%, He 9.17% with balance air. KCO was expressed as mmol·min⁻¹·kPa⁻¹·L⁻¹. A breath-holding period of 10 s (Jones and Meade method) and discard/sample volumes of 750 mL were adopted [11]. Smokers refrained from smoking from 24 h before the measurement; no correction for haemoglobin levels was made since this has only a very limited effect [12]. Predicted values and the LLN were calculated by using appropriate reference values [10, 13]. KCO values below the LLN were considered abnormal.

CT scanning
All participants received low-dose CT, using 16-detector multidetector computed tomography (MDCT) scanners (MX8000 IDT or Brilliance 16P; Philips Medical Systems, Cleveland, OH, USA), at baseline and after follow-up. Scan data were obtained in spiral mode, with 16 × 0.75-mm collimation and in full inspiration. No spirometric gating was applied since this does not improve repeatability of lung density measurements [14, 15]. Axial images were reconstructed with a 1.0-mm thickness at 0.7-mm increments. All scans were reconstructed with a soft reconstruction filter (Philips B, Siemens B30f; Philips Medical Systems, Cleveland, OH, USA) at a 512 × 512 matrix. Exposure settings were 30 mAs at 120 kVp or 140 kVp, depending on the participant’s weight. This low-dose CT protocol has previously been used to quantify emphysema in COPD patients and heavy smokers [16, 17]. All CT scans were automatically analysed by software developed in-house [18]. Airways were excluded to ensure that only lung parenchyma was analysed [19].

Emphysema quantification
Severity of emphysema was based on the 15th percentile technique. This technique provides the Hounsfield Units (HU) point below which 15% of the voxels are distributed. The lower the 15th percentile values are thus closer to -1000 HU, the more emphysema is present. This method of emphysema quantification has been validated against pathology [20] and has been applied in multiple studies [21]. The 15th percentile was preferred to the %-950 HU measurement [22]. However, a secondary analysis was done using the %-950 HU as emphysema severity measure, which is defined as the proportion of low-density voxels below -950 HU, and is reported in the online supplementary material.

Statistical evaluation
Mean ± SD values were calculated for normally distributed data and median and 25th–75th percentile values for non-normally distributed data. Unpaired t-tests and Chi-squared tests were used to test differences between groups as appropriate. Pearson’s correlations were used to establish associations between variables at baseline.

Emphysema severity (15th percentile) and FEV1/FVC at the end of the observation period were the primary end-points and were analysed by multiple linear regression analyses. KCO at baseline was the main explanatory factor. Adjustments were made for baseline 15th percentile and FEV1/FVC, age, height, body mass index (BMI), pack-yrs, and smoking status (current or former smoker). 15th percentile progression and FEV1/FVC decline were calculated by subtracting follow-up values adjusted by multiple linear regression analyses from observed baseline values. A p-value of <0.05 was considered significant. All statistical analyses were performed using SPSS 18 for Windows (SPSS, Chicago, IL, USA).

The mean ± SD 15th percentile was -937.7 ± 18.5 HU. Baseline KCO was significantly correlated with 15th percentile at baseline (r = 0.23, p < 0.001). Participants with an abnormal KCO (< LLN) had significantly more (p = 0.002) CT-quantified
emphysema as compared to subjects with a normal KCO, -940.1±19.0 HU and -935.1±17.6 HU, respectively.

RESULTS

Baseline demographics, lung function and CT-quantified emphysema

609 participants underwent follow-up CT-scanning and spirometry. Of these 609 participants, 87 were excluded due to missing or incomplete baseline KCO values, resulting in 522 participants being included in the current study. There were no significant differences in baseline age, height, BMI, pack-yrs, smoking status, spirometry results or CT-quantified emphysema severity between included participants and participants who were excluded due to missing or incomplete KCO values.

The mean ± SD age of the participants was 60.1±5.4 yrs and 251 (48.1%) were current smokers. FEV1/FVC was 71.6%±9.0 of predicted and mean ± SD KCO was 1.23±0.25, which is 81.8±16.5% of predicted. Further baseline demographics and lung function parameters for the total study population are listed in table 1. More than half of the participants, 272 (52.1%), had an abnormal KCO at baseline and the baseline KCO was significantly correlated with baseline FEV1/FVC (r=-0.46, p<0.001). Demographics and lung function parameters stratified by normal and KCO <LLN are presented in table 2. The majority of participants, 424 (81.2%), had no airflow obstruction (FEV1/FVC >LLN). Of the participants with no airflow obstruction, 213 (50.2%) had a lowered KCO. Figure 1 illustrates the baseline FEV1/FVC, 15th percentile and KCO by smoking status.

Association of KCO with progression of CT-quantified emphysema

Median (interquartile range) follow-up time was 2.75 (2.7–3.0) yrs. The mean 15th percentile after follow-up was -944.4±17.9 HU and the mean ± SD progression of emphysema was 6.3±5.5 HU. The statistical model explained 68% of the variance in the 15th percentile after follow-up (r²=0.68). Baseline values of FEV1/FVC, 15th percentile and KCO and smoking status (current or former smoker) proved to be significant predictive factors for the progression of 15th percentile (table 3). A 0.25 lower baseline KCO (being the SD of KCO in this sample) predicted an additional 1.6 HU lower 15th percentile after follow-up (p<0.001). The effect of KCO is illustrated in figure 2. The effects of the other significant covariates in the model are listed in table 3. Age, height, BMI and pack-yrs smoked were not significantly associated with 15th percentile progression.

An additional analysis was performed to test whether the association of KCO with 15th percentile progression was independent of the baseline level of FEV1/FVC. An interaction term between baseline FEV1/FVC and baseline KCO was inserted in the statistical model. The baseline FEV1/FVC value was significantly (p<0.001) associated with progression of 15th percentile; a 1% lower baseline KCO value predicted an additional 0.3 HU lower 15th percentile. However, the interaction term was not significant (p=0.099) indicating that the association of baseline KCO was similar in participants with different levels of airflow obstruction.

Using the %-950 HU approach as measure of emphysema severity yielded similar results as using the 15th percentile (see online supplementary material).

Association of KCO with decline in FEV1/FVC

Mean absolute ± SD FEV1/FVC after follow-up was 70.2±9.4%. The statistical model explained 80% of the variance in FEV1/FVC after follow-up (r²=0.80). Baseline values of FEV1/FVC and KCO proved to be significant predictive factors for FEV1/FVC decline as shown in table 4. Adjusted decline was 1.44±0.92% during 3-yr follow-up. To put this decline in

<table>
<thead>
<tr>
<th>TABLE 1 Baseline demographics</th>
<th>Subjects n 522</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age yrs</td>
<td>60.1±5.4</td>
</tr>
<tr>
<td>Height m</td>
<td>1.78±0.07</td>
</tr>
<tr>
<td>BMI kg m⁻²</td>
<td>26.8±3.3</td>
</tr>
<tr>
<td>Follow-up yrs</td>
<td>2.75±1.78</td>
</tr>
<tr>
<td>Pack-yrs smoking</td>
<td>41.3±18.7</td>
</tr>
<tr>
<td>Current smokers %</td>
<td>48.1</td>
</tr>
<tr>
<td>FEV1 L</td>
<td>3.35±0.72</td>
</tr>
<tr>
<td>FEV1 % pred</td>
<td>97.6±18.2</td>
</tr>
<tr>
<td>FEV1/FVC absolute %</td>
<td>71.6±9.0</td>
</tr>
<tr>
<td>Participants with airflow obstruction %</td>
<td>98±18.8</td>
</tr>
<tr>
<td>KCO mmol⁻¹ min⁻¹ kPa⁻¹ L⁻¹</td>
<td>1.23±0.025</td>
</tr>
<tr>
<td>KCO % pred</td>
<td>81.8±16.5</td>
</tr>
<tr>
<td>15th percentile emphysema score on CT HU</td>
<td>-937.8±18.5</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD or median (interquartile range), unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; CT: computed tomography.

| TABLE 2 Baseline demographics stratified by normal and transfer coefficient of the lung for carbon monoxide (KCO) < lower limit of normal (LLN) |
|-------------------------------------------------|-----------------|
| Normal KCO                                      | KCO <LLN        |
| Subjects n                                      | 250             | 272             |
| Age yrs                                        | 60.6±5.4        | 59.7±5.3        | 0.067 |
| Height m                                       | 1.78±0.06       | 1.78±0.06       | 0.155 |
| BMI kg m⁻²                                      | 26.8±3.3        | 26.8±3.3        | 0.256 |
| Follow-up yrs                                  | 2.75±1.78       | 2.75±1.78       | 0.325 |
| Pack-yrs smoking                               | 40.4±19.1       | 42.1±18.3       | 0.326 |
| Current smokers %                              | 91 (36.4)       | 160 (59.4)      | <0.001* |
| FEV1 L                                         | 3.40±0.68       | 3.30±0.75       | 0.142 |
| FEV1 % pred                                    | 99.6±16.6       | 95.8±19.3       | 0.015* |
| FEV1/FVC absolute %                            | 74.4±7.4        | 69.2±9.6        | <0.001* |
| Participants with airflow obstruction %         | 27 (10.8)       | 71 (26.1)       | <0.001* |
| KCO mmol⁻¹ min⁻¹ kPa⁻¹ L⁻¹                      | 1.43±0.15       | 1.05±0.17       | <0.001* |
| KCO % pred                                     | 95.6±9.6        | 69.7±10.8       | <0.001* |
| 15th percentile emphysema score on CT HU        | 985.1±17.6      | -940.1±19.0     | 0.002* |

Data are presented as mean ± SD; median (interquartile range) or n(%), unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; CT: computed tomography.

* P<0.05; #: FEV1/FVC < LLN; #: statistically significant.
perspective, the expected 3-yr decline in FEV1/FVC according to appropriate reference values is 0.5% [10]. When a subject showed a 0.25 lower $K_{CO}$ (being 1 SD) compared with another subject, that subject suffered from an additional 0.78% lower FEV1/FVC after follow-up ($p = 0.001$) (table 4, and fig. 3).

The analysis with insertion of an interaction term between baseline FEV1/FVC and baseline $K_{CO}$ showed that the association of $K_{CO}$ with FEV1/FVC decline was independent of the baseline FEV1/FVC value as the interaction term was not significant ($p = 0.133$).

**DISCUSSION**

In the present study, we showed that a lower $K_{CO}$ value was associated with an increase of CT-quantified emphysema and a larger decline in FEV1/FVC during a 3-yr follow-up of male heavy-smokers. This association proved to be independent of the level of FEV1/FVC. $K_{CO}$, a simple and patient-friendly measurement, may therefore help to detect current and former smokers who are susceptible to a more rapid progression of CT-quantified emphysema and decline in lung function independently of their FEV1/FVC level.

Parameters like the FEV1/FVC do not reflect the presence or the severity of emphysema accurately [23]. Mild emphysema does not always lead to a FEV1/FVC $<70\%$ (or $<\text{LLN}$), and thus COPD can be missed if only spirometry is performed. However, in daily practice the evaluation of subjects at risk for (or with established) COPD is usually based on spirometry [10]. Unfortunately, spirometry fails to discriminate between chronic bronchitis and emphysema. The latter may be assessed by CT scanning; however, a disadvantage of CT scanning is that it exposes subjects to radiation and is relatively expensive. It is therefore not performed on a regular basis, which is also true for repeatedly performed low-dose CT scans. An advantage of CT-scanning is the additional information that is obtained on the distribution of emphysema, but it is questionable whether this information is clinically relevant [24]. Conversely, diffusion testing is harmless, less expensive and can thus be applied routinely and more frequently than CT scanning. This is strengthened by the finding that of the 272 participants with a $K_{CO}$ below the LLN, only 71 had an FEV1/FVC below the LLN. This finding again illustrates that in an at-risk population with a high smoking history, performing only spirometry may miss a large number of subjects with abnormal diffusion tests results.

The association of a lower baseline $K_{CO}$ with progression of emphysema and decline of FEV1/FVC was independent of the level of baseline FEV1/FVC as there were no significant interactions between them. This is an important finding because it illustrates that it is useful to perform $K_{CO}$ measurements in heavy smokers, independently of their FEV1/FVC. Only taking in account the FEV1/FVC, and not the $K_{CO}$, in the evaluation of heavy smokers may result in missing subjects who will suffer from a stronger progression of 15th percentile. The assessment of $K_{CO}$ thus may have important prognostic implications.

To our knowledge, there are no longitudinal studies examining the predictive value of $K_{CO}$ on FEV1/FVC decline. One study has examined the predictive value of the diffusion coefficient

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Change</th>
<th>15th percentile HU</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$K_{CO}$</td>
<td>0.25 lower</td>
<td>-1.6 HU</td>
<td>0.59-2.60</td>
<td>0.002</td>
</tr>
<tr>
<td>Baseline FEV1/FVC absolute %</td>
<td>1% lower</td>
<td>-0.3 HU</td>
<td>0.19-0.43</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Current versus ex-smoker</td>
<td>+3.2 HU</td>
<td>1.30-5.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Baseline 15th percentile HU</td>
<td>1 HU lower</td>
<td>-0.67 HU</td>
<td>-0.61--0.72</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity. *: a 0.25 lower $K_{CO}$ at baseline predicts an additionally 1.6 HU lower 15th percentile after 3-yr follow-up.
of the lung for carbon monoxide (DL,CO) on FEV1 decline and showed that DL,CO differentiates smokers who will experience a rapid FEV1 decline [25]. The included subjects were comparable with our population. They were also relatively healthy but slightly younger. Although these authors measured the DL,CO instead of the KCO, their results support our findings that the KCO may help to identify subjects with a more rapid lung function decline.

As for the association between KCO and lung function decline, literature evaluating the predictive value on emphysema progression is scarce. Cross-sectional studies have shown that the KCO is lower in subjects with pathologically defined as well as with CT-detected emphysema [26–28]. We confirm these findings by showing that there was a significant correlation between KCO and 15th percentile at baseline (r = 0.23). However, the correlation was not as strong as previously reported, which may be due to the fact that the included subjects were relatively healthy and without severe emphysema.

There are a number of strengths to our study. First, emphysema scores were automatically quantified, which eliminates interobserver variability known to be present in the visual assessment of emphysema. Secondly, the study was performed in one centre and only one type of CT scanner was used, excluding possible scanner bias due to different algorithms used by different types of CT scanners. Thirdly, the same diffusion testing equipment was used. This is especially important since it is known that large variability may exist in KCO measurements between different lung function laboratories [29]. Fourthly, only heavy smoking, but relatively healthy participants were included. This makes the results especially applicable to subjects who are at risk of progression of emphysema and airflow obstruction. The earlier-mentioned cross-sectional studies were almost all restricted to (severe) COPD subjects. Finally, because

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Change</th>
<th>Change in FEV1/FVC %</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>KCO</td>
<td>0.25 lower</td>
<td>-0.78 %</td>
<td>0.31–1.14</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Baseline FEV1/FVC absolute %</td>
<td>1% lower</td>
<td>-0.90 %</td>
<td>0.85–0.94</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*: a 0.25 lower Kco at baseline predicts an additionally 0.78% lower FEV1/FVC after 3-yrs of follow-up.
of the large sample size, we could extensively correct for potential confounding factors like age, pack-yrs smoked and smoking status. This makes our reported results more precise.

This study also has some limitations. First, only pre-bronchodilator spirometry was obtained, which could have resulted in lower measured FEV1/FVC values. As a result, the percentage of participants without airflow obstruction could actually be lower. However, because we treated FEV1/FVC as quantitative we do not expect that this has affected our results. Secondly, no females were included due to the inclusion criteria of the study. This is unfortunate because the prevalence of COPD is increasing in females. Previous studies showed that emphysema scores in females are lower than in males, and that females also show lesser progression of emphysema after follow-up [30–32]. Lastly, we performed analyses with both the 15th percentile and the %-950 HU; the results of the latter are described in the online supplementary material. The outcomes of the analyses with %-950 HU as emphysema measurement are in the similar direction as by using 15th percentile and underscore our conclusions. It should, however, be realised that the 15th percentile takes into account not only the regions with markedly reduced density, but the whole lung, while the %-950 HU is less sensitive for lung density changes of the whole lung.

In conclusion, we have shown that current and former heavy smokers with lower baseline Kco scores in females are lower than in males, and that females also show sex differences in emphysema phenotype in smokers without airflow obstruction. Previous studies showed that emphysema progresses faster in females. This is unfortunate because the prevalence of COPD is increasing in females. Rates of smoking cessation are lower in females. Previous studies showed that emphysema progresses faster in females. Previous studies showed that emphysema progresses faster in females.

**SUPPORT STATEMENT**

This work was supported by EU FP7 grant number 201379, COPACETIC study.

**STATEMENT OF INTEREST**

None declared.

**REFERENCES**


